share_log

Oppenheimer Initiates Coverage On Immunovant With Outperform Rating, Announces Price Target of $50

Moomoo 24/7 ·  Mar 28 06:49

Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Price Target of $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment